The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

This trial is testing whether adding a radioactive drug called 177Lu-TLX591 (which targets a protein called PSMA on prostate cancer cells) to standard-of-care treatment helps men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. **You may be eligible if...** - You are male, 18 or older, with confirmed prostate cancer that has spread (metastatic) - Your cancer has become "castration-resistant" (progressing despite testosterone suppression) - You have already received at least 12 weeks of a hormonal treatment (such as enzalutamide, abiraterone, apalutamide, or darolutamide) - Your cancer tests positive for the PSMA protein on a special PET scan - You are in reasonably good health (ECOG 0–2) with a life expectancy of at least 6 months - Your PSA is rising or you have new/worsening lesions **You may NOT be eligible if...** - You have brain metastases larger than 1 cm - You have not had the required PSMA PET/CT scan - Your prior docetaxel treatment was less than 6 months ago Talk to your doctor to see if this trial is right for you.